Cannabis Law Report

NOVEMBER 15, 2021

–(BUSINESS WIRE)– #earnings — Virpax ® Pharmaceuticals, Inc. Finally, we recently acquired the worldwide rights to VRP324, which is an intranasal pharmaceutical-grade cannabidiol product candidate for the management of epilepsy in children (rare pediatric disease) and adults. About Virpax Pharmaceuticals.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

MMJ Recs

APRIL 1, 2024

Studies have suggested that CBD may help manage chronic pain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment. Its non-addictive nature and minimal side effects make it an attractive alternative to conventional pharmaceuticals for many individuals seeking natural remedies.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

The Cannigma

JUNE 1, 2021

France’s (experimental) medical cannabis program. In March, 2021, France launched a two-year experiment to gauge the effectiveness of a nationwide medical marijuana program and to prepare the ground for future distribution, according to the Health Ministry. Children may be eligible in cases of refractory epilepsy or cancer.

Law 113

Law Epilepsy Programs Patients 113

Cannabis Law Report

AUGUST 4, 2022

Following the keenly anticipated June approval of its cannabis-derived Epidiolex, GW Pharmaceuticals $GWPH has finally launched the rare epilepsy drug in the United States. Epidiolex is also currently being evaluated for other epilepsy conditions, including tuberous sclerosis complex. Press Release.

Epilepsy 52

Epilepsy Therapy Patients Treatment 52

NORML

AUGUST 26, 2019

So, it shouldn’t be a huge surprise that Virginia didn’t launch a medical marijuana program until 2015, nearly two decades after California. And it took extensive, concerted efforts from marijuana law reform organizations like NORML to negotiate with Virginia’s Republican Party to get the program finally running.

Marijuana 216

Marijuana Legalization Programs Oil 216

The Cannigma

JUNE 25, 2022

Poland established a medical cannabis program in 2017, which allows for a range of cannabis products to be prescribed for a range of medical conditions. Poland’s medical cannabis program. Patients must have a doctor’s prescription as well as permission from a regional pharmaceutical inspector to obtain cannabis products.

Legalization 108

Legalization Supply Chain Chronic Pain Tincture 108

Veriheal

FEBRUARY 21, 2023

Opioid Abuse and Drug Overdose Deaths Are Higher in States With Restrictive MMJ Policies Despite ongoing political debates about the limitations of medical marijuana programs, a 2019 study published in the Journal of Patient-Centered Research and Reviews provided further evidence of how MMJ-restrictive states inadvertently impact their patients.

Access 98

Access Patients Chronic Pain Conditions 98

Veriheal

JULY 21, 2022

This month, patients will no longer require a medical cannabis card to participate in Virginia’s medical cannabis program. On July 1, the process of procuring pharmaceutical-approved cannabis was simplified for individuals residing across the state, where the first licensed medical marijuana dispensary opened its doors in August 2020.

Access 104

Access Dispensary Patients Programs 104

MedicalJane

OCTOBER 3, 2019

The United States Department of Defense and GW Pharmaceuticals are collaborating on a new clinical trial at the Montefiore Medical Center in New York. Dr. Eric Hollander, the Director of the Autism and Obsessive Compulsive Spectrum Program and Anxiety and Depression Program at Montefiore Hospital, is leading the clinical trial.

Clinical Trials 74

Clinical Trials Epilepsy Pharmaceutical Treatment 74

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Montefiore Medical Center in New York and GW Pharmaceuticals are examining the effects of a cannabis compound when administered to children on the autism spectrum.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

Veriheal

JULY 26, 2023

The first batch of authorized pharmaceutical retailers is expected to start selling between late August and early September. ” On the 14th of June, Georgia’s Pharmacy Board held a hearing as regards the proposed rules. And Turnage has hinted that the regulation would be formalized soon.

Oil 98

Oil Patients Access THC 98

MMJ Recs

MAY 15, 2022

This initial MMJ legislation only allowed patients suffering from intractable epilepsy to use cannabis oil. But in the years since 2017, lawmakers have steadily improved Virginia’s medical marijuana program and made it accessible to a wider range of people. Recently, Virginia legalization has changed in several ways.

Patients 52

Patients Marijuana Pharmaceutical Dispensary 52

Cannabis Law Report

JULY 26, 2021

OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced a number of updates regarding its Phase IIb clinical study in Tourette Syndrome using the proprietary cannabinoid-based treatment- SCI-110. About SciSparc (OTCQB: SPRCY): SciSparc Ltd.

Research and Development 105

Research and Development Supply Chain Pharmaceutical Treatment 105

Veriheal

MAY 17, 2021

Many of them even offer the ability for visiting medical cannabis patients from other states to participate in their programs. Please don’t further the lie by voting for any form of legalization beyond the pharmaceutical remedies already available under state law.” ” State Doctors Oppose Legalization in Alabama.

Legalization 86

Legalization Pharmaceutical Therapy Chronic Pain 86

SpeedWeed

AUGUST 9, 2021

The first supply of medical cannabis for pediatric patients with epilepsy at the Buenos Aires National Children’s Garrahan Hospital was finally delivered. The hospital’s young patients will now receive treatment from pharmaceutical-grade cannabis oil, purified and highly concentrated. Shutterstock. It modified Law No.

Epilepsy 52

Epilepsy Research and Development Medicine Patients 52

Freedom Leaf

OCTOBER 15, 2018

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. The push for CBD is not surprising, whether it’s sold as a pharmaceutical drug or as a “dietary supplement” similar to gingko biloba or St.

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

MMJ Recs

FEBRUARY 3, 2024

Pennsylvania Medical Cannabis Program and Philadelphia Marijuana Dispensaries The Pennsylvania Medical Cannabis Program serves as the foundation for medical marijuana accessibility in Philadelphia. This can lead to a decreased reliance on pharmaceuticals that may adversely affect patients’ health and overall lifestyle.

Legislation 52

Legislation Law Marijuana Dispensary 52

SpeedWeed

AUGUST 12, 2021

The FDA objected to the application, pointing out that just a few years ago it had already sent CBD down the path of active ingredients in pharmaceutical drugs—putting the cannabinoid at odds with the ingestible food and beverage and dietary supplement market. “CBD is the active ingredient in the approved drug product, Epidiolex.

CBD 52

CBD Pharmaceutical Food DEA 52

MMJ Recs

FEBRUARY 18, 2021

Medical marijuana is being used in the US to treat a wide variety of illnesses, such as chronic pain, glaucoma, migraine, muscle spasms, insomnia, arthritis, PTSD, and epilepsy. Sadly, the citizens of many of the world’s nations are still not able to enjoy the benefits of a well-run MMJ program.

Legalization 52

Legalization Marijuana Treatment Programs 52

Canna Care Docs

SEPTEMBER 18, 2020

These bills created the affirmative defense for possession of THC-A oil for the treatment of epilepsy. These oils are extracted by the licensed Pharmaceutical Processors that have been selected to grow, process, and dispense medical cannabis in Virginia. July 2020 brought substantial changes to the medical cannabis program.

Pharmaceutical 98

Pharmaceutical Conditions Patients Oil 98

Kind Meds (Cannabis Education Blog)

APRIL 29, 2019

At the age of three, Charlotte tested positive for a gene marker that indicates Dravet syndrome, a rare form of epilepsy that begins in infant or toddlerhood and causes more severe and more frequent seizures over time. In fact, CBD has fewer ill effects than pharmaceutical seizure medications. Worsening Conditions.

Oil 86

Oil Strains Pharmaceutical Research and Development 86

Veriheal

NOVEMBER 10, 2020

The experiment will allow participating companies to import cannabis and the companies who wish to participate in the experiment will be obliged to give participants free medical cannabis which has to comply with the pharmaceutical standards and good manufacturing practice. .

Chronic Pain 76

Chronic Pain Pharmaceutical Patients Epilepsy 76

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Montefiore Medical Center in New York and GW Pharmaceuticals are examining the effects of a cannabis compound when administered to children on the autism spectrum.

Research and Development 40

Research and Development Epilepsy Clinical Trials Treatment 40

Cannabis Law Report

AUGUST 2, 2021

OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

MARCH 2, 2020

First up, cannabis has now been scientifically validated as a treatment for two severe forms of childhood epilepsy (more on this in a moment). Back in 2018, the DEA rescheduled GW Pharmaceuticals ‘ (NASDAQ: GWPH) cannabis-based epilepsy medicine, Epidiolex, following its regulatory approval by the FDA.

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

Cannabis Law Report

JANUARY 24, 2020

Last year , Ireland’s Minister for Health signed legislation to commence a medical cannabis program that is to operate on a pilot basis for five years. Additionally, severe refractory (treatment-resistant) epilepsy also qualifies. A third has now been added to the list; an oral solution from Canada’s Tilray – THC10:CBD10.

Oil 59

Oil Epilepsy Conditions Treatment 59

Cannabis Law Report

JANUARY 4, 2022

In addition, the surge in medical marijuana production owing to its increasing demand in the pharmaceutical sector is further propelling overall growth. The increasing prevalence of epilepsy and other sleep disorders is aiding the product adoption thereby, positively contributing to the segment growth. Mgc Pharmaceuticals Ltd.

Legalization 52

Legalization Supply Chain Chronic Pain Sleep 52

Veriheal

AUGUST 31, 2020

Program between St. Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. She is entering the 8-year Dual Admit B.S./M.D. Bonaventure University and George Washington University School of Medicine. .

Research and Development 117

Research and Development Education Agriculture Patients 117

Veriheal

JULY 28, 2021

However, the leadership council of the North Carolina-based Eastern Band of Cherokee Indians made serious headway in May, when the council agreed to legalize small amounts of pharmaceutical-grade cannabis for use on tribal territory. A “North Carolina Cannabis Research Program” would be formed on behalf of The University of North Carolina.

Seed-To-Sale 59

Seed-To-Sale Research and Development Pharmaceutical Conditions 59

CannaTech

JANUARY 16, 2019

Pharmaceutical grade cannabis is relatively new in parts of the world. This statistic accounts for medicines treating patients with epilepsy, anxiety, depression, chronic pain, and other illnesses. This article has primarily offered a small dose of the pharmaceutical side of the medical cannabis market in Latin America.

Access 89

Access Patients Pharmaceutical Education 89

Cannabis Law Report

DECEMBER 20, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. About Virpax Pharmaceuticals. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of epilepsy in children (a rare pediatric disease) and adults.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. The perception that CBD is a wonder-drug version of cannabis — particularly known for its uses to treat epilepsy — that doesn’t get you high. Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

Veriheal

DECEMBER 28, 2021

Many of these medical conditions are featured on the list of qualifying criteria for medical cannabis programs in the 37 U.S. For example, pharmaceutical-grade cannabis is being sold across the fast-evolving retail pharmacy landscape. Amyotrophic lateral sclerosis (ALS). Alzheimer’s. Chronic pain. Depression. Multiple Sclerosis.

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

MGC Pharma

FEBRUARY 20, 2018

The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon. Notably, 41% of the Cannabis users stopped using opioids altogether.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100

Cannabis Law Report

AUGUST 6, 2019

The scientists aim to make life more bearable for people suffering through chemotherapy, epilepsy, multiple sclerosis and chronic pain. Several dozen students have already tried to land spots on the enrollment list even though the program may take more than a year to roll out. Expect some flavorful THC-infused products.

Chronic Pain 40

Chronic Pain Agriculture Oil THC 40

Cannabis Chronicles

JANUARY 2, 2019

drug regulators approved the first marijuana-based pharmaceutical to treat kids with a form of epilepsy, and billions of investment dollars poured into cannabis companies. Canada ushered in broad legalization, and Mexico’s Supreme Court set the stage for that country to follow. Attitudes have been rapidly evolving and changing.

Legalization 100

Legalization Research and Development Recreational Data 100

Veriheal

JANUARY 15, 2021

The MCAP, also known as the Medical Cannabis Access Programme , is a five-year pilot program that will allow patients that meet a stringent requirement list to access and utilize cannabis. Severe and Treatment-Resistant Refractory Epilepsy. This legislation outlines the requirements for certain patients to have access to the MCAP.

Legalization 57

Legalization Therapy Access Legislation 57